Search Results

Invivoscribe and Complete Genomics announced that they had entered a partnership to develop and commercialize biomarker tests on Complete Genomics’ NGS platforms.

We are pleased to announce that Invivoscribe’s LeukoStrat® CDx FLT3 Mutation Assay has been approved by BSI and the EMA as a Class C CDx assay, meeting the stringent new IVDR 2017/746) requirements.

Invivoscribe is excited to announce that the LeukoStrat® CDx FLT3 Mutation Assay has been approved by the U.S. Food and Drug Administration to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA®.

Invivoscribe is pleased to announce that their LeukoStrat CDx FLT3 Mutation Assay® has received updated reimbursement by Japan’s Ministry of Health, Labor and Welfare to aid in the selection of patients with newly diagnosed FLT3-ITD positive acute myeloid leukemia who may be eligible to receive treatment with Daiichi Sankyo’s VANFLYTA®.

Hitachi High-Tech Corporation (“Hitachi High-Tech”) has entered into a strategic partnership (the Partnership) with Invivoscribe, Inc. (“Invivoscribe”), a global provider of blood cancer testing kits and services, by undertaking a minority investment-based, third-party allotment of shares.

◆Investment to support services growth. ◆Industry veterans join board of directors, including John Chickosky as Executive Chairman, and Greg Swanberg and Martin LeBlanc as Directors.

Kronos Bio, Inc., a company dedicated to transforming the lives of those affected by cancer, and Invivoscribe, a global provider of diagnostic kits and services for oncology, announced their agreement to develop a companion diagnostic for use with Kronos Bio’s investigational therapy, entospletinib.

Invivoscribe is pleased to announce that they have filed a supplemental Pre-Market Approval (sPMA) submission with the U.S. Food and Drug Administration (FDA) Center for Devices and Radiological Health (CDRH) for the use of the LeukoStrat® CDx FLT3 Mutation Assay as the companion diagnostic for Daiichi Sankyo’s investigational drug quizartinib.

We are in an unprecedented time in neurotherapeutics. Medicines that address the causative disease biology underlying central nervous system